AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Chemical Business NewsBase - Press Release)
Over a third of patients taking GlaxoSmithKline's Requip (ropinirole HCl) for Restless Legs Syndrome (RLS) in clinical trials experienced significant improvement in their symptoms at one week, according to the results presented at the Associated Professional Sleep Societies 18th Annual Meeting in Philadelphia. The results were from combined data from three double blind, placebo controlled trials of Requip in RLS, which included 618 patients, aged 18 to 79 years. Requip is under review by the US Food and Drug Administration for the treatment of RLS. There is no currently approved treatment for RLS in the US. In the three double-blind trials, 618 patients were randomised to receive Requip or placebo, taken once a day for 12 weeks one to three hours before bedtime. During weeks ...